Sickle Cell Treatment Decisions In The Post-Oxbryta Era – Archyde

Deutsches Ärzteblatt

Factuality

Ownership

San Diego – The first drug based on the gene scissors technology Crispr approved in the European Union (EU) is about to be launched on the German market. Experts expect that the gene therapy Casgevy (Exa-cel), which is used to treat sickle cell disease and...

archyde

Factuality

Ownership

Sickle Cell Treatment Decisions In The Post-Oxbryta Era – Archyde

Archyde Sickle Cell Treatment⁤ Options Limited Following Drug Withdrawal Table of Contents 1. Sickle Cell Treatment⁤ Options Limited Following Drug Withdrawal 2. Limited Treatment Landscape 3. The Impact of Oxbryta’s Withdrawal 4. Current Treatment Landscape and Future Directions 5. Looking Ahead: A Call for Continued Research Table of Contents 1. Sickle Cell Treatment⁤ Options Limited Following […] You can read the full story here: Sickle Cell …

The BMJ

Factuality

Ownership

Re: Acute painful crisis in adults with sickle cell disease. Response to Wolf.

Agreement: I AgreeBody: Dear Editor Thank you for seeking my response to Dr. Wolf’s valid concerns about transfusion in sickle cell disease (SCD) with which I agree. Transfusion to sickle cell disease in developed countries, where the blood donor pool is predominantly Caucasian, lacking the R0 antigen is often complicated by alloantibody formation thereby complicating future transfusions. Iron overload is a potential complication of chronic bloo…